Literature DB >> 22742545

Crystalline nephropathies.

Leal C Herlitz1, Vivette D D'Agati, Glen S Markowitz.   

Abstract

CONTEXT: The kidney is a favored site for crystal deposition because of the high concentration of ions and molecules reached at the level of the renal tubules in the course of filtration. This review focuses on crystalline nephropathies in 4 broad categories: (1) dysproteinemia- associated, (2) drug-induced, (3) calcium-containing, and (4) metabolic or genetic.
OBJECTIVE: To provide a framework for accurate identification of the diverse types of crystals encountered in the kidney in order to formulate an appropriate differential diagnosis and guide additional testing and treatment. DATA SOURCES: Review of pertinent published literature along with practical experience gained in a high-volume renal pathology laboratory.
CONCLUSIONS: Accurate identification of crystals encountered in the kidney is essential in detecting conditions ranging from hematologic malignancy to drug toxicity to metabolic disorders. Detailed clinical-pathologic correlation is needed to accurately diagnose the underlying cause of most crystalline nephropathies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22742545     DOI: 10.5858/arpa.2011-0565-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  31 in total

1.  [Acute renal failure in a 75-year-old woman with a high-output ileostoma].

Authors:  S Teege; T Wiech; O M Steinmetz
Journal:  Internist (Berl)       Date:  2017-05       Impact factor: 0.743

2.  Bone oxaloma-a localized manifestation of bone oxalosis.

Authors:  Eun Ji Choi; Choong Guen Chee; Wanlim Kim; Joon Seon Song; Hye Won Chung
Journal:  Skeletal Radiol       Date:  2019-11-25       Impact factor: 2.199

3.  Proceedings of the 2013 National Toxicology Program Satellite Symposium.

Authors:  Susan A Elmore; Michael C Boyle; Molly H Boyle; Michelle C Cora; Torrie A Crabbs; Connie A Cummings; Margarita M Gruebbel; Crystal L Johnson; David E Malarkey; Elizabeth F McInnes; Thomas Nolte; Cynthia C Shackelford; Jerrold M Ward
Journal:  Toxicol Pathol       Date:  2013-12-13       Impact factor: 1.902

Review 4.  Differential diagnosis of glomerular disease: a systematic and inclusive approach.

Authors:  Lee A Hebert; Samir Parikh; Jason Prosek; Tibor Nadasdy; Brad H Rovin
Journal:  Am J Nephrol       Date:  2013-09-13       Impact factor: 3.754

Review 5.  An update on the role of the inflammasomes in the pathogenesis of kidney diseases.

Authors:  Murthy N Darisipudi; Felix Knauf
Journal:  Pediatr Nephrol       Date:  2015-07-16       Impact factor: 3.714

6.  Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study.

Authors:  Shigemasa Tani; Ken Nagao; Atsushi Hirayama
Journal:  Clin Drug Investig       Date:  2015-12       Impact factor: 2.859

Review 7.  Management of nephrotoxicity of chemotherapy and targeted agents: 2020.

Authors:  Varsha Chiruvella; Pavan Annamaraju; Achuta K Guddati
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

8.  Light Chain Proximal Tubulopathy: Clinical and Pathologic Characteristics in the Modern Treatment Era.

Authors:  Michael B Stokes; Anthony M Valeri; Leal Herlitz; Abdullah M Khan; David S Siegel; Glen S Markowitz; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2015-09-15       Impact factor: 10.121

9.  The effect of hypercalcemia on allograft calcification after kidney transplantation.

Authors:  Aygül Çeltik; Sait Şen; Mümtaz Yılmaz; Meltem Seziş Demirci; Gülay Aşçı; Abdülkerim Furkan Tamer; Banu Sarsık; Cüneyt Hoşcoşkun; Hüseyin Töz; Ercan Ok
Journal:  Int Urol Nephrol       Date:  2016-08-13       Impact factor: 2.370

Review 10.  Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias.

Authors:  Shveta S Motwani; Leal Herlitz; Divya Monga; Kenar D Jhaveri; Albert Q Lam
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.